INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 184 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $341,463 | -26.0% | 18,418 | -55.8% | 0.00% | 0.0% |
| Q2 2023 | $461,158 | -19.2% | 41,696 | -1.9% | 0.00% | 0.0% |
| Q1 2023 | $570,585 | +0.4% | 42,486 | -7.4% | 0.00% | 0.0% |
| Q4 2022 | $568,470 | +215.8% | 45,899 | +255.0% | 0.00% | – |
| Q3 2022 | $180,000 | -2.2% | 12,931 | -2.7% | 0.00% | – |
| Q2 2022 | $184,000 | -17.1% | 13,293 | -3.0% | 0.00% | – |
| Q1 2022 | $222,000 | -12.9% | 13,702 | -12.5% | 0.00% | – |
| Q4 2021 | $255,000 | +8.1% | 15,662 | -1.5% | 0.00% | – |
| Q3 2021 | $236,000 | -27.2% | 15,901 | -2.3% | 0.00% | -100.0% |
| Q2 2021 | $324,000 | -68.3% | 16,278 | -63.3% | 0.00% | -50.0% |
| Q1 2021 | $1,023,000 | -23.8% | 44,328 | -18.5% | 0.00% | -50.0% |
| Q4 2020 | $1,343,000 | -56.5% | 54,405 | -26.9% | 0.00% | -55.6% |
| Q3 2020 | $3,090,000 | -14.5% | 74,398 | -1.3% | 0.01% | -25.0% |
| Q2 2020 | $3,612,000 | -23.7% | 75,398 | +0.4% | 0.01% | -36.8% |
| Q1 2020 | $4,732,000 | – | 75,135 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |